This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
TCLF 2020
Presentations

Brentuximab Vedotin | Lymphoma
Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with BV and CHP (A+CHP) for patients with CD30+ PTCL

Brentuximab Vedotin | Lymphoma
Exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in frontline treatment of pts with CD30+ PTCL (ECHELON-2): impact of consolidative SCT